| Alphalytik Pharmaservice–Certania: investment, 202409 acquisition of Alphalytik Pharmaservice GmbH by Certania |
2024-09-04 |
| Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202409– collab expansion using EMERGE platform to advance PancAlert screening test |
2024-09-04 |
| Saiba Animal Health–Boehringer: investment, 202409 acquisition €na of Saiba Animal Health AG by Boehringer Ingelheim |
2024-09-03 |
| Lucid Genomics–SEVERAL: investment, 202408 pre-seed financing round €1.3m led by Caesar Ventures |
2024-09-02 |
| Allogenetics–Carma Fund: investment, 202408 first financing round totalling €3.4m incl co-lead investor Carma Fund |
2024-08-29 |
| Allogenetics–Lower Saxony (govt): investment, 202408 first financing round totalling €3.4m incl co-lead investor NBank Capital |
2024-08-29 |
| Allogenetics–OTHER: investment, 202408 first financing round totalling €3.4m incl several business angels |
2024-08-29 |
| Allogenetics–SEVERAL: investment, 202408 first financing round €3.4m led by NBank Capital + Carma Fund |
2024-08-29 |
| Irubis–SEVERAL: investment, 202408 financing round pre-Series A led by new investor BioProcess360 Partners |
2024-08-29 |
| Bayer–NextRNA Therapeutics: small-molecule cancer drugs targeting lncRNAs, 202408– collab strategic up to $547m for two programmes |
2024-08-28 |
| Novartis–Lindy Biosciences: biologics drug delivery, 202408– license + collab ww excl $20m upfront + $934m milestones using microglassifcation |
2024-08-28 |
| Vandria–Dolby Family Ventures: investment, 202408 financing round Series A 2nd closing totalling CHF10.3m incl new investor Dolby Family Ventures |
2024-08-21 |
| Vandria–Hevolution Foundation: investment, 202408 financing round Series A 2nd closing totalling CHF10.3m incl new investor Hevolution Foundation |
2024-08-21 |
| Vandria–SEVERAL: investment, 202408 financing round Series A 2nd closing CHF10.3m bringing total Series A to CHF28.3m |
2024-08-21 |
| Reliant AI–Inovia Capital: investment, 202408 seed financing round totalling $11.3m incl co-lead investor Inovia Capital |
2024-08-20 |
| Reliant AI–PERSON: investment, 202408 seed financing round totalling $11.3m incl co-investor Mike Volpi |
2024-08-20 |
| Reliant AI–SEVERAL: investment, 202408 emerges from stealth with seed financing round $11.3m co-led by Tola Capital + Inovia Capital |
2024-08-20 |
| Reliant AI–Tola Capital: investment, 202408 seed financing round totalling $11.3m incl co-lead investor Tola Capital |
2024-08-20 |
| Genedata–Danaher: investment, 202408 acquisition of Genedata that will join Danaher’s Life Science segment |
2024-08-19 |
| Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility |
2024-08-15 |
| Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m |
2024-08-15 |
| Balderton Capital–SEVERAL: investment, 202408 announced $615m Early Stage Fund IX |
2024-08-12 |
| Balderton Capital–SEVERAL: investment, 202408 announced $685m Growth Fund II |
2024-08-12 |
| Exscientia–Recursion Pharmaceuticals: investment, 202408– merger announced with former Recursion shareholders holding 74% of combined company |
2024-08-08 |
| PL BioScience–Avant Bio: investment, 202408 financing round Series A totalling €7.8m incl new investor Avant Bio LLC |
2024-08-08 |
| PL BioScience–b.value: investment, 202408 financing round Series A totalling €7.8m incl new investor b.value AG |
2024-08-08 |
| PL BioScience–Better Ventures: investment, 202408 financing round Series A totalling €7.8m incl new investor Better Ventures |
2024-08-08 |
| PL BioScience–Brightlands Venture Partners: investment, 202408 financing round Series A totalling €7.8m incl existing investor BVP Fund IV |
2024-08-08 |
| PL BioScience–LePure Biotech: investment, 202408 financing round Series A totalling €7.8m incl new investor LePure Biotech |
2024-08-08 |
| PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors |
2024-08-08 |
| PL BioScience–TechVision Fonds: investment, 202408 financing round Series A totalling €7.8m incl existing investor TechVision Fonds |
2024-08-08 |
| SphingoTec–SEVERAL: investment, 202408 financing round Series C €5m led by Think.Health Ventures |
2024-08-08 |
| Bruker–Novalix: drug discovery technology, 202408– strategic collab to enable new paradigms in drug discovery |
2024-08-07 |
| IDRx–Bertarelli Group: investment, 202408 financing round Series B totalling $120m incl existing + co-investor Forge Life Science Partners |
2024-08-07 |
| IDRx–Merck (DE): investment, 202408 financing round Series B totalling $120m incl existing + co-investor Merck KGaA |
2024-08-07 |
| IDRx–Nextech: investment, 202408 financing round Series B totalling $120m incl existing + co-investor funds managed by Nextech Invest Ltd |
2024-08-07 |
| IDRx–SEVERAL: investment, 202408 financing round Series B $120m led by RA Capital + Commodore Capital + Blackstone Multi-Asset Investing |
2024-08-07 |
| NEC–Asahi Glass: contract manufacturing, 202408– collab developm production techn + supply cancer vaccine NECVAX-NEO1 by AGC Biologics + NEC Bio Tx |
2024-08-07 |
| Novalix–Bruker: investment, 202408 strategic minority investment €na by Bruker |
2024-08-07 |
| Leon-Nanodrugs–Albany Private Equity: investment, 202408 financing round Series D incl existing + co-investor Albany Private Equity Holindgs Pty Ltd |
2024-08-06 |
| Leon-Nanodrugs–Baden-Württemberg (govt): investment, 202408 financing round Series D incl new + lead investor LBBW Venture Capital |
2024-08-06 |
| Leon-Nanodrugs–CD-Venture: investment, 202408 financing round Series D incl existing + co-investor CD-Venture GmbH |
2024-08-06 |
| Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202408 financing round Series D incl existing + co-investor Eckenstein-Geigy-Stiftung |
2024-08-06 |
| Leon-Nanodrugs–SEVERAL: investment, 202408 financing round Series D led by new investor LBBW Venture Capital |
2024-08-06 |
| Leon-Nanodrugs–Signet Healthcare Partners: investment, 202408 financing round Series D incl existing + co-investor Signet Healthcare Partners |
2024-08-06 |
| Leon-Nanodrugs–TVM: investment, 202408 financing round Series D incl existing + co-investor TVM Life Science Innovation I LP |
2024-08-06 |
| Nestlé–Seres Therapeutics: microbiome-based drug, 202408– acquisition of Vowst (SER-109) assets for up to $488.5m by Nestlé Health Science |
2024-08-06 |
| Seres Therapeutics–Nestlé: investment, 202408– equity investment $15m acquisition 14.3m shares common stock at $1.05/share by Nestlé |
2024-08-06 |
| BASF–Biomatter Designs: enzyme design, 202408 supply existent customer BASF |
2024-08-05 |
| Biomatter Designs–SEVERAL: investment, 202408 seed financing round €6.5m led by Inventure + UVC Partners |
2024-08-05 |
| Biomatter Designs–UVC Partners: investment, 202408 seed financing round totalling €6.5m co-led by UVC Partners |
2024-08-05 |
| Kirin–Biomatter Designs: enzyme design, 202408 collab existent development of enzymes for production of Human Milk Oligsaccharides (HMOs) |
2024-08-05 |
| Neogen–Biomatter Designs: enzyme design, 202408 supply existent customer Neogen |
2024-08-05 |
| AIRNA–SEVERAL: investment, 202407 financing round Series A extension $60m led by Forbion brings total Series A to $90m |
2024-07-31 |
| Ono Pharmaceutical–Systasy Bioscience: drug target discovery, 202407– collab research fees + milestones to identify + validate targets in neurology |
2024-07-31 |
| Systasy Bioscience–MC Services: public relations, 202407 service existent by MC Services |
2024-07-31 |
| Synthetica Pioneering–Boehringer: investment, 202407 financing round Series A incl co-lead investor Boehringer Ingelheim Venture Fund |
2024-07-30 |
| Synthetica Pioneering–SEVERAL: investment, 202407 financing round Series A led by Boehringer Ingelheim Venture Fund + Temasek |
2024-07-30 |
| Agilent–Sigsense Technologies: lab management software, 202407 supply existent Sigsense technology available via Agilent CrossLab Connect |
2024-07-29 |
| Nerio Therapeutics–Boehringer: investment, 202407 acquisition up to $1.3b of Nerio Therapeutics by Boehringer |
2024-07-29 |
| Sigsense Technologies–Agilent: investment, 202407 acquisition €na of Sigsense by Agilent |
2024-07-29 |
| Confo Therapeutics–SEVERAL: investment, 202407 financing round Series B €60m led by Ackermans & van Haaren |
2024-07-26 |
| Deepc–Bertelsmann: investment, 202407 financing round Series A extension totalling €13m incl existing + co-lead investor Bertelsmann Investments |
2024-07-25 |
| Deepc–CSS (CH): investment, 202407 financing round Series A extension totalling €13m incl new + co-investor SwissHealth Ventures |
2024-07-25 |
| Deepc–SEVERAL: investment, 202407 financing round Series A extension €13m led by Sofinnova Partners + Bertelsmann Investments |
2024-07-25 |
| Deepc–Sofinnova: investment, 202407 financing round Series A extension totalling €13m incl existing + co-lead investor Sofinnova Partners |
2024-07-25 |
| Deepc–United Kingdom (govt): investment, 202407 financing round Series A extension totalling €13m incl new + co-investor KHP Ventures |
2024-07-25 |
| Deepc–Winning Mindset Ventures: investment, 202407 financing round Series A extension totalling €13m incl existing + co-investor Winning Mindset |
2024-07-25 |
| Micropep Technologies–BPI Green Tech Investment: investment, 202407 financing round Series B totalling $29m co-led by new investor BPI GTI |
2024-07-25 |
| Micropep Technologies–SEVERAL: investment, 202407 financing round Series B $29m led by Zebra Impact Ventures + BPI Green Tech Investment |
2024-07-25 |
| Micropep Technologies–Z Impact Ventures: investment, 202407 financing round Series B totalling $29m co-led by new investor Zebra Impact Ventures |
2024-07-25 |
| Dren Bio–Novartis: investment, 202407 equity investment $25m in connection with strategic r+d alliance |
2024-07-24 |
| Novartis–Dren Bio: antibody cancer drug, 202407– strategic collab $125m upfront + $2.85b milestones + royalties RnD bispecifc antibodies for cancer |
2024-07-24 |
| Palvella Therapeutics–Pieris: investment, 202407– reverse merger with former Palvella shareholders owning 82% + new name Palvella Therapeutics Inc |
2024-07-24 |
| Palvella Therapeutics–SEVERAL: investment, 202407– private placement $78.9m incl $18.9m conversion of convertible notes |
2024-07-24 |
| BioNTech–Triastek: 3D drug printing, 202407– collab developm + license $10m upfront + $1.2b milestones plus royalties 3D printed oral RNA drugs |
2024-07-23 |
| Regenosca–Business Angels Switzerland: investment, 202407 pre-seed financing round totalling CHF1m incl investor Business Angels Switzerland |
2024-07-22 |
| Regenosca–OTHER: investment, 202407 pre-seed financing round totalling CHF1m incl private investors |
2024-07-22 |
| Regenosca–SEVERAL: investment, 202407 pre-seed financing round CHF1m with private investors + Businesss Angels Switzerland + Venture Kick |
2024-07-22 |
| Regenosca–Venture Kick: investment, 202407 pre-seed financing round totalling CHF1m incl investor Vemture Kick |
2024-07-22 |
| Smart rTMS–Neurocare: investment, 202407 acquisition of Smart TMS by Neurocare Group |
2024-07-22 |
| GRO Biosciences–Bayer: investment, 202407 financing round Series B totalling $60.3m incl existing + co-investor Leaps by Bayer |
2024-07-19 |
| GRO Biosciences–SEVERAL: investment, 202407 financing round Series B $60.3m co-led by Atlas Venture + Access Biotechnology |
2024-07-19 |
| Lignopure–Lower Saxony (govt): investment, 202407 equity financing round totalling €2.4m incl lead investor NBank Capital |
2024-07-17 |
| Lignopure–NiedersachsenMetall: investment, 202407 equity financing round totalling €2.4m incl co-investor Niedersachsen Beteiligungs GmbH & Co KG |
2024-07-17 |
| Lignopure–OTHER: investment, 202407 equity financing round totalling €2.4m incl existing investors |
2024-07-17 |
| Lignopure–OTHER: investment, 202407 equity financing round totalling €2.4m incl a Family Office as co-investor |
2024-07-17 |
| Lignopure–RaakWark Kaptaal: investment, 202407 equity financing round totalling €2.4m incl co-investor RaakWark Kaptaal |
2024-07-17 |
| Lignopure–SEVERAL: investment, 202407 equity financing round €2.4m led by NBank Capital |
2024-07-17 |
| SK Group–Full-Life Technologies: radionuclide-drug conjugate, 202407– license ww excl up to $571.5m to FL-091 anti-NTSR1 to SK Biopharmaceuticals |
2024-07-17 |
| Asceneuron–EQT: investment, 202407 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences - LSP Dementia Fund |
2024-07-16 |
| Asceneuron–GSK: investment, 202407 financing round Series C totalling $100m incl existing + co-investor GSK Equities Investments Ltd |
2024-07-16 |
| Asceneuron–JnJ: investment, 202407 financing round Series C totalling $100m incl existing + co-investor JnJ Innovation JJDC Inc |
2024-07-16 |
| Asceneuron–Merck (DE): investment, 202407 financing round Series C totalling $100m incl existing + co-investor M Ventures |
2024-07-16 |
| Asceneuron–Novo Group: investment, 202407 financing round Series C totalling $100m incl lead investor Novo Holdings |
2024-07-16 |
| Asceneuron–OrbiMed: investment, 202407 financing round Series C totalling $100m incl new + co-investor OrbiMed |
2024-07-16 |
| Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings |
2024-07-16 |
| Asceneuron–Sofinnova: investment, 202407 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners |
2024-07-16 |
| Asceneuron–SR One: investment, 202407 financing round Series C totalling $100m incl new + co-investor SR One |
2024-07-16 |
| Catalym–Bioqube Ventures: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Bioqube Ventures |
2024-07-16 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
